Cargando…

Primary prevention implantable cardioverter defibrillator in cardiac resynchronization therapy recipients with advanced chronic kidney disease

INTRODUCTION: The implantable cardioverter defibrillator (ICD) is effective for the prevention of sudden cardiac death (SCD) in patients with heart failure and a reduced ejection fraction (HFrEF). The benefit of the ICD in patients with advanced CKD, remains elusive. Moreover, the benefit of the ICD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldenberg, Ido, Kutyifa, Valentina, Zareba, Wojciech, Huang, David Tsu-Chau, Rosero, Spencer Z., Younis, Arwa, Schuger, Claudio, Gao, Anna, McNitt, Scott, Polonsky, Bronislava, Steinberg, Jonathan S., Goldenberg, Ilan, Aktas, Mehmet K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482044/ https://www.ncbi.nlm.nih.gov/pubmed/37680559 http://dx.doi.org/10.3389/fcvm.2023.1237118

Ejemplares similares

Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT)
por: Aktas, Mehmet K., et al.
Publicado: (2020)

Need for pacing in patients who qualify for an implantable cardioverter‐defibrillator: Clinical implications for the subcutaneous ICD
por: Kutyifa, Valentina, et al.
Publicado: (2020)

Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator
por: Younis, Arwa, et al.
Publicado: (2020)

Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention
por: Saxena, Shireen, et al.
Publicado: (2022)

Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy
por: Younis, Arwa, et al.
Publicado: (2021)

Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block
por: Biton, Yitschak, et al.
Publicado: (2015)

Prognostic Importance of Defibrillator‐Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure
por: Biton, Yitschak, et al.
Publicado: (2019)

Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events
por: Szepietowska, Barbara, et al.
Publicado: (2016)

CHA(2)DS(2)‐VASc Score and the Risk of Ventricular Tachyarrhythmic Events and Mortality in MADIT‐CRT
por: Nof, Eyal, et al.
Publicado: (2019)

Genetic variant annotation scores in congenital long QT syndrome
por: Younis, Arwa, et al.
Publicado: (2023)

Predictors of Atrial Fibrillation During Long‐Term Implantable Cardiac Monitoring Following Cryptogenic Stroke
por: Riordan, Michael, et al.
Publicado: (2020)

Assessment of absolute risk of life-threatening cardiac events in long QT syndrome patients
por: Wang, Meng, et al.
Publicado: (2022)

Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death
por: Kutyifa, Valentina, et al.
Publicado: (2018)

Insertable cardiac monitor‐guided early intervention to reduce atrial fibrillation burden following catheter ablation: Study design and clinical protocol (ICM‐REDUCE‐AF trial)
por: Tankut, Sinan S., et al.
Publicado: (2023)

Confirm Rx insertable cardiac monitor for primary atrial fibrillation detection in high‐risk heart failure patients (Confirm‐AF trial)
por: Aktas, Mehmet K., et al.
Publicado: (2022)

Recurrent ventricular tachycardia in a patient with COVID-19 vaccine-associated myocarditis: a case report
por: Ojo, Amole, et al.
Publicado: (2023)

Implantable Cardioverter-Defibrillator for Primary Prevention in Asia
por: Younis, Arwa, et al.
Publicado: (2023)

Risk Prediction in Women With Congenital Long QT Syndrome
por: Goldenberg, Ilan, et al.
Publicado: (2021)

Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience
por: Kutyifa, Valentina, et al.
Publicado: (2014)

The common apolipoprotein A-1 polymorphism −75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction
por: Block, Robert, et al.
Publicado: (2009)

Manual vs. automatic capture management in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators
por: Murgatroyd, Francis D., et al.
Publicado: (2010)

Junctional AV ablation in patients with atrial fibrillation undergoing cardiac resynchronization therapy (JAVA-CRT): results of a multicenter randomized clinical trial pilot program
por: Steinberg, Jonathan S., et al.
Publicado: (2022)

Predictive value of global longitudinal strain by left ventricular ejection fraction
por: Medvedofsky, Diego, et al.
Publicado: (2023)

Left-to-right atrioventricular activation delay, a novel measure of AV-conduction, predicts clinical outcomes in non-LBBB patients
por: Beierle, A S, et al.
Publicado: (2023)

AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol
por: Kutyifa, Valentina, et al.
Publicado: (2020)

Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure admission
por: Kosztin, Annamaria, et al.
Publicado: (2017)

Loss of cardiac resynchronization therapy in a patient with a biventricular implantable cardioverter-defibrillator
por: Alasti, Mohammad, et al.
Publicado: (2017)

Economic analysis of remote monitoring in patients with implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators in the Trento area, Italy
por: Marini, Massimiliano, et al.
Publicado: (2023)

The economic impact of remote control in patients with implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators: single center experience
por: Marini, M, et al.
Publicado: (2023)

Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33)
por: Foo, Fang Shawn, et al.
Publicado: (2019)

Association Between Subcutaneous Implantable Cardioverter Defibrillator Preimplantation Screening and the Response to Cardiac Resynchronization Therapy
por: Jing, Ran, et al.
Publicado: (2020)

Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator
por: Wan, Chingping, et al.
Publicado: (2013)

The importance of leadless pacemaker positioning in relation to subcutaneous implantable cardioverter-defibrillator sensing in completely leadless cardiac resynchronization and defibrillation systems
por: Elliott, Mark K., et al.
Publicado: (2021)

Importance of Implantable Cardioverter‐Defibrillator Back‐Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta‐Analysis
por: Barra, Sérgio, et al.
Publicado: (2015)

One Indication for an Extravascular Cardiac Resynchronization Therapy Defibrillator: Lessons from a Combination Therapy Case with Epicardial Cardiac Resynchronization Therapy and a Subcutaneous Implantable Cardioverter Defibrillator
por: Ishii, Natsuko, et al.
Publicado: (2021)

Implantation of a Resynchronization Implantable Cardioverter Defibrillator in a Patient with Persistent Left Superior Vena Cava
por: Antonelli, Dante, et al.
Publicado: (2007)

Editorial to implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33)
por: Minamiguchi, Hitoshi
Publicado: (2019)

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry
por: Steiner, Hillel, et al.
Publicado: (2016)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
por: Sherazi, Saadia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9o98avt65igh14ol7ik1ghtcta